Open AccessPB2060: THE MDS‐SPECIFIC COMORBIDITY INDEX (MDS‐CI) PREDICTS SURVIVAL INDEPENDENTLY FROM DIPSS AND MIPSS70 IN PATIENTS WITH OVERT MYELOFIBROSIS NOT ELIGIBLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION.
Author(s) -
Koster K.L.,
Messerich N.M.,
Volken T.,
Cogliatti S.,
Lehmann T.,
Holbro A.,
Benz R.,
Graf L.,
Demmer I.,
Jochum W.,
Silzle T.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000851072.40949.cf
Subject(s) - myelofibrosis , medicine , international prognostic scoring system , comorbidity , transplantation , hematopoietic stem cell transplantation , oncology , myelodysplastic syndromes , bone marrow